Who We Are

Our Purpose

Eicos Sciences is dedicated to bringing life-changing therapies to Systemic Sclerosis (SSc) patients who suffer from digital ischemic episodes (Raynaud’s Phenomenon) and have limited or no treatment options. SSc is a rare autoimmune disease characterized by inflammation, immune system dysfunction, vasculopathy, and fibrosis of the skin and internal organs. Over time, progressive changes in digital vasculature can cause more severe and longer lasting ischemic episodes that can lead to digital ulcers, gangrene, and ultimately result in amputations. Our focus is fueled by our commitment to develop the first FDA-approved treatment that can improve outcomes in patients experiencing this painful and debilitating condition.


SHAL JACOBOVITZ, Chief Executive Officer

  • 30+ years experience in the pharma industry in leadership roles (Actelion, F. Hoffman LaRoche, Abbott Canada, Nordic Labs & Marion Merrill Dow [now Aventis])
  • Former CEO of the American College of Cardiology (2013 – 2018) and led the 52,000+ member organization in its mission to transform cardiovascular care
  • Former President of Actelion Pharmaceuticals (2004 – 2013), acquired by J&J for $30B

WADE BENTON, PHARM.D., Chief Development Officer 

  • 20 years experience in drug development and academic research in Systemic Sclerosis, PAH, Cystic Fibrosis, Pediatrics
  • 15 years experience developing and commercializing prostacyclin analogs

KEVIN CHRISTAL, Chief Operating Officer

  • 20 years experience in commercial operations and business development spanning numerous disease areas
  • 15 years experience developing and commercializing prostacyclin analogs

DINESH KHANNA, M.D., MSc, Chief Medical Officer

  • Professor of Medicine and Director of the Scleroderma Program at University of Michigan
  • A leading expert in Systemic Sclerosis research and patient care with publication of over 300 peer review manuscripts